Poster: Evaluation of Bispecific Antibody Efficacy and Drug-Induced Cytokine Release
Download the full poster here.
Bispecific antibodies have been shown to have several distinct advantages over monoclonal antibodies. However, testing their effectiveness and safety in vivo has proven to be a specific challenge for this promising therapeutic class. The researchers at JAX have developed a human stem cell (HSC) humanized mouse model for testing both efficacy and quantifying cytokine release in response to bispecific antibody treatment.
In a recent poster, Yao and colleagues from JAX presented their work, which evaluated an EGFR bispecific T cell engager (BiTE), using an EGFR-positive MDA-MD-231 orthotopic breast cancer model in a CD34+ HSC NSG™ mouse model.
In terms of efficacy, the authors observed that there was complete tumor regression in 2 weeks post BiTE treatment. Furthermore, at four weeks post-treatment, tumors at approximately 400 mm3 were inhibited. To assess immunotoxicity, 16 hours following the first two doses of BiTE treatment, the authors observed elevated levels of human cytokines IFN-g, IL-6, and IL-10. However, following continuous dosing, these levels returned to baseline.